Clinical Trial Update: CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating CpG 7909 in combination with trastuzumab (Herceptin) for metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CPG 7909 (CpG 7909)
• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Breast | Phase 2 | Status: COMPLETED